A New Day in Cancer Treatment: FDA Approves BMS’s Opdualag
Bristol Myers Squibb (BMS) achieved a monumental milestone when the U.S. Food and Drug Administration approved Opdualag (nivolumab and relatlimab-rmbw) for the treatment of patients 12 and older with unresctable or metastatic melanoma. The decision is based on the...
Moderna and Pfizer are seeking FDA approval for second COVID-19 boosters.
Moderna formally requested the FDA grant emergency authorization for a second booster shot of its COVID-19 vaccine for all adults over 18 who have received approved vaccines. Earlier this week, Pfizer and its partner BioNTech also requested authorization for a second...
COVID-19 Update: The Diabetes Connection, WHO Concerned about BA.2
Viral infections can have a broad range of side effects, such as myocarditis, and COVID-19 is no different. There is evidence that COVID-19 infection might be linked to an increase in diabetes, particularly Type 1 diabetes, an autoimmune disease most commonly...
FDA approves Four Cancer Clinical Trials
Several biopharma companies celebrate the U.S. Food and Drug Administration’s approval for clinical trials involving therapeutics for cancer treatment, including Sonnet BioTherapeutics and Adagene. Sonnet BioTherapeutics evolved into a clinical biopharmaceutical...
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
Arrowhead Pharmaceuticals, Inc. has announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-RAGE, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of the receptor for...
CDE Approves the Inclusion of Hexvix® in the Clinical Real-world Evidence Pilot Study
Asieris Pharmaceuticals, in accordance with advice from the National Medical products Administration Center for Drug Evaluation (CDE), has approved the inclusion of Asieris’s drug Hexvic®, a drug for the diagnosis of bladder cancer, in the clinical real-world world...